tetano
Editor, Senior Moderator
AAPS J
. 2025 Mar 11;27(2):58.
doi: 10.1208/s12248-025-01043-8. Functional Activity and Binding Specificity of Small Ankyrin Repeat Proteins Called Ankyrons Against SARS-CoV-2 Variants
Yun-Jong Park[SUP] 1 [/SUP], Wojciech Jankowski[SUP] 1 [/SUP], Nicholas C Hurst[SUP] 2 [/SUP], Jeremy W Fry[SUP] 2 [/SUP], Nikolai F Schwabe[SUP] 2 [/SUP], Linda C C Tan[SUP] 2 [/SUP], Zuben E Sauna[SUP] 3 [/SUP]
Affiliations
Effective management of COVID-19 requires clinical tools to treat the disease in addition to preventive vaccines. Several recombinant mAbs and their cocktails have been developed to treat COVID-19 but these have limitations. Here, we evaluate small ankyrin repeat proteins called Ankyrons that were generated to bind with high affinity to the SARS-CoV-2 virus. Ankyrons are ankyrin repeat proteins comprised of repetitions a structural module. Each module consists of a β-turn followed by two antiparallel α-helices. The Ankyrons™ are directly selected in vitro from a highly diverse library of around a trillion clones in ribosome display and like antibodies can bind with high affinity to almost any target. We assessed Ankyrons that were generated against the wild-type SARS-CoV-2 and the Delta (B.1.617.2) and Omicron (BA.1) variants in a binding assay. We determined that all Ankyrons were specific in that they did not bind to MERS. While all Ankyrons bound with high affinity to the variant they were generated against, some also showed cross-reactivity to all three SARS-CoV-2 variants. Binding assays are useful for screening analytes but do not provide information about clinical effectiveness. Therefore, we used a pseudovirus-based neutralization assay to show that five of the Ankyrons evaluated neutralized all three strains of SARS-CoV-2. We have provided a workflow for the evaluation of novel Ankyrons against a viral target. This suggests that Ankyrons could be useful for rapidly developing new research tools for studying other emerging infectious diseases rapidly with the optional further potential for developing Ankyrons into diagnostic and even therapeutic applications.
Keywords: Ankyrons; Biolayer Interferometry (BLI); Neutralization assay; SARS-CoV-2; Teralibrary.
. 2025 Mar 11;27(2):58.
doi: 10.1208/s12248-025-01043-8. Functional Activity and Binding Specificity of Small Ankyrin Repeat Proteins Called Ankyrons Against SARS-CoV-2 Variants
Yun-Jong Park[SUP] 1 [/SUP], Wojciech Jankowski[SUP] 1 [/SUP], Nicholas C Hurst[SUP] 2 [/SUP], Jeremy W Fry[SUP] 2 [/SUP], Nikolai F Schwabe[SUP] 2 [/SUP], Linda C C Tan[SUP] 2 [/SUP], Zuben E Sauna[SUP] 3 [/SUP]
Affiliations
- PMID: 40069439
- DOI: 10.1208/s12248-025-01043-8
Effective management of COVID-19 requires clinical tools to treat the disease in addition to preventive vaccines. Several recombinant mAbs and their cocktails have been developed to treat COVID-19 but these have limitations. Here, we evaluate small ankyrin repeat proteins called Ankyrons that were generated to bind with high affinity to the SARS-CoV-2 virus. Ankyrons are ankyrin repeat proteins comprised of repetitions a structural module. Each module consists of a β-turn followed by two antiparallel α-helices. The Ankyrons™ are directly selected in vitro from a highly diverse library of around a trillion clones in ribosome display and like antibodies can bind with high affinity to almost any target. We assessed Ankyrons that were generated against the wild-type SARS-CoV-2 and the Delta (B.1.617.2) and Omicron (BA.1) variants in a binding assay. We determined that all Ankyrons were specific in that they did not bind to MERS. While all Ankyrons bound with high affinity to the variant they were generated against, some also showed cross-reactivity to all three SARS-CoV-2 variants. Binding assays are useful for screening analytes but do not provide information about clinical effectiveness. Therefore, we used a pseudovirus-based neutralization assay to show that five of the Ankyrons evaluated neutralized all three strains of SARS-CoV-2. We have provided a workflow for the evaluation of novel Ankyrons against a viral target. This suggests that Ankyrons could be useful for rapidly developing new research tools for studying other emerging infectious diseases rapidly with the optional further potential for developing Ankyrons into diagnostic and even therapeutic applications.
Keywords: Ankyrons; Biolayer Interferometry (BLI); Neutralization assay; SARS-CoV-2; Teralibrary.